
Remix launched with a vision to transform patients’ lives through modulation of RNA processing. Our breakthrough science enables the identification of small molecules that influence the expression of disease‑driving mRNAs and proteins. We focus on diseases of high unmet medical need and are committed to operating with scientific rigor and urgency. With a proprietary in‑house technology platform, we have rapidly generated multiple discovery programs advancing toward the clinic. Remix Therapeutics was recognized as one of BioSpace’s Best Places to Work in Boston 2025 and is backed by leading life sciences investors.
Reporting to the Chief Scientific Officer, the Vice President of Nonclinical Drug Safety and Toxicology is a key position within the R&D leadership team and will lead nonclinical aspects of all the company’s pipeline programs. As the most senior toxicology expert within the organization, the VP will be responsible for providing strategic and operational leadership for the toxicology group across the portfolio of discovery, early development, and late development programs. The Non-Clinical Safety and Toxicology leader will partner cross-functionally across therapeutic areas with colleagues in drug discovery, translational, and clinical development functions, ensuring toxicology and nonclinical safety data is shared and communicated transparently and plays a role in informing strategy at all stages of each program’s development.
Areas of specific responsibility and attention will include the following:
$293,000 - $358,000 USD
This range reflects the expected base salary for this position, plus bonus, equity, and benefits as applicable. Actual salaries may vary based on factors, such as skill, experience, and qualification for the role.

Remix is working to transform patient's lives through modulation of RNA processing and addressing drug targets in diseases of high unmet medical need. We are a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster™ technology platform leverages cutting-edge data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's innovative therapeutic approach led to the discovery of REM-422, a first-in-class RNA processing modulator in oncology, now being evaluated in Phase 1 clinical studies to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (HR-MDS) and adenoid cystic carcinoma (ACC).